Cambridge Isotope Labs (CIL), Tewksbury, Mass, through a partnership with Alsachim, Illkirch-Graffenstaden, France, now offers an assortment of unlabeled and stable isotope-labeled antiviral drug standards and their metabolites to assist in covid-19 research and therapy development.
“We are thrilled to join forces with CIL in order to answer US customers’ needs and deliver crucial compounds for covid-19 therapeutic monitoring,” says Jean-Francois Hoeffler, PhD, president of Alsachim.
The products are available through CIL in convenient package sizes, and are suitable for use as internal standards in therapeutic monitoring and quantitative analysis.
“We are excited to partner with Alsachim to offer their high-quality drug standards to provide a much-needed service to those US pharmaceutical and biotech companies that are actively pursuing therapies to treat covid-19,” says Maureen Duffy, vice president of sales and marketing for CIL.
For more information, visit on CIL.
